World Health Organization Raises Alert Over Critical Shortage of Weight-Loss Injections
Less than 10% of individuals eligible to benefit from obesity jabs like Wegovy can access them, states the WHO as it publishes its inaugural advice on the medications.
Given more than one billion individuals worldwide currently living with obesity, it is urging more widespread and fairer access to these injectable treatments.
Per estimates, over two billion are projected to be obese by 2030 without intervention.
"Our new guidance recognises that obesity is a lifelong illness that can be managed with comprehensive and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major hurdles to universal access to the treatments that can help people shift significant body mass, says the agency.
GLP-1 Therapy Scarcity
Despite the present most optimistic case, the production of GLP-1 therapies could only cover around 100 million people – less than 10% of the global need, per the health organization.
The recommendation encourages nations and manufacturers to widen access, via approaches such as patent sharing.
The intellectual property rights on a key compound – the primary component of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
How Obesity Drugs Function
The injections replicate a biological compound to reduce digestion speed, reduce hunger and enhance feelings of fullness so individuals reduce food intake.
People typically see weight reduction after several weeks of starting on the regular doses.
Evidence indicates patients may regain a significant portion after a year of stopping the drug, when their typical appetite resume.
To be above a healthy weight elevates your likelihood for experiencing diseases, like diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight affects people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
